6 completed, 4 terminated, 2 not yet recruiting, 2 withdrawn. 8 Phase 1, 8 Phase 2, 2 Phase 3.
Follow bemarituzumab: new trials by email Literature Review of bemarituzumab trials Research Report on bemarituzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment Bemarituzumab, FLOT - GastroEsophageal Cancer | Phase 1 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 27 | 2026-02-20 | 2025-06-05 |
| Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b Bemarituzumab + Flot regimen - Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b | Phase 2 | Withdrawn | Institut Cancerologie de l'Ouest | 2026-01-01 | 2026-01-21 | |
| AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer Bemarituzumab, Bevacizumab - Endometrial Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | Centre Leon Berard | 2025-10-15 | 2026-04-23 | |
| Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil - Metastatic Gastro-esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 126 | 2025-03-03 | 2026-01-07 |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Bemarituzumab - Solid Tumors | Phase 1 / Phase 2 | Terminated | Amgen | 260 | 2022-09-23 | 2026-06-22 |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Bemarituzumab, CAPOX, SOX - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Amgen | 72 | 2022-05-17 | 2026-07-29 |
| A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) Bemarituzumab, Docetaxel, Pembrolizumab - Squamous-Cell Non-Small-Cell Lung Cancer | Phase 1 | Terminated | Amgen | 74 | 2022-03-29 | 2025-03-25 |
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. Bemarituzumab, Nivolumab, Chemotherapy - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Terminated | Amgen | 515 | 2022-03-14 | 2026-09-10 |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Bemarituzumab, mFOLFOX6, Placebo - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | Amgen | 547 | 2022-03-07 | 2026-05-27 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer Bemarituzumab, Placebo, Modified FOLFOX6 - Gastric Cancer | Phase 2 | Completed | Five Prime Therapeutics, Inc. | 155 | 2018-09-14 | 2024-02-28 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer Bemarituzumab, Modified FOLFOX6 - Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic | Phase 1 | Completed | Five Prime Therapeutics, Inc. | 12 | 2017-11-30 | 2024-02-28 |
| A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer FPA144 - Gastric or Gastroesophageal Cancer | Phase 1 | Completed | Amgen | 6 | 2017-06-12 | 2023-06-22 |
| PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Trastuzumab, ABT-806, Bemarituzumab - Adenocarcinoma | Phase 2 | Completed | University of Chicago | 80 | 2015-01-20 | 2021-04-08 |
| Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors FPA144 - Advanced Solid Tumors, Gastric Cancer | Phase 1 | Completed | Five Prime Therapeutics, Inc. | 79 | 2014-11-01 | 2024-06-04 |
| An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer FPA144 - Recurrent Bladder Cancer | No longer available | Five Prime Therapeutics, Inc. | 2021-12-13 |
Stomach Neoplasms (6) · Adenocarcinoma (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Amgen (6) · Five Prime Therapeutics, Inc. (4) · Centre Leon Berard (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fujian Cancer Hospital (1) · Institut Cancerologie de l'Ouest (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · University of Chicago (1)
United States (9) · Japan (7) · South Korea (7) · France (6) · Taiwan (6) · Belgium (5) · Poland (5) · Spain (5) · Australia (4) · China (4) · Hungary (4) · Italy (4) · Portugal (4) · Romania (4) · Argentina (3)
Daniel Catenacci, MD (1) · Elizabeth Smyth (1) · Jiunluan Li, MD (1) · Judith Raimbourg, MD (1) · Maike Collienne (1) · Markus Moehler (1) · Salah Eddin Al-Batran, Prof. Dr. (1) · Sylvie Lorenzen, Prof. Dr. (1)
PMID 38308771, PMID 40341124, PMID 32965540, PMID 36244398
2023 (4), 2017 (1)